Increased expression of CD33 in the brain has been suggested to be associated with increased amyloid plaque burden, while the peripheral level of CD33 in Alzheimer’s disease (AD) patients and its role in AD remain unclear. This evidence concerns the gene CD33 and early-onset autosomal dominant Alzheimer disease.